Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 4/20 | 0.69 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.59 |
| ▸ | JAK1 | P23458 | 4/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | CDK9 | P50750 | 2/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.50 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3212521 | 0.89 | NUDT1 (0.67) | NUDT1EGLN2JAK1JAK2DYRK3 | |
| SCHEMBL3099050 | 0.83 | NUDT1 (0.58) | NUDT1EGLN2JAK1JAK2JAK3 | |
| SCHEMBL2144054 | 0.82 | NUDT1 (1.00) | NUDT1EGLN2JAK1JAK2DYRK1A | |
| SCHEMBL3087585 | 0.82 | NUDT1 (0.69) | NUDT1EGLN2JAK1JAK2JAK3 | |
| SCHEMBL5462584 | 0.78 | KDM4E (0.70) | NUDT1EGLN2DYRK3CCNT1CCNA2 | |
| SCHEMBL10855803 | 0.78 | NUDT1 (0.46) | NUDT1EGLN2DYRK3CCNT1CCNA2 | |
| SCHEMBL1422839 | 0.78 | NUDT1 (0.64) | NUDT1EGLN2JAK1JAK2JAK3 | |
| SCHEMBL3304801 | 0.78 | JAK1 (0.75) | NUDT1EGLN2JAK1JAK2DYRK1A | |
| SCHEMBL3601961 | 0.78 | NUDT1 (0.78) | NUDT1EGLN2JAK1JAK2JAK3 | |
| SCHEMBL3215698 | 0.77 | NUDT1 (0.67) | NUDT1EGLN2JAK1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057158-B1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LTD (GB) | 2015-08-12 | — | — | EP | claimed |
| US-8883820-B2 | Triazole derivatives as kinase inhibitors | CELLZOME LTD. (GB) | 2014-11-11 | — | — | US | claimed |
| US-8431596-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-04-30 | — | — | US | claimed |
| US-20100227800-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2010-09-09 | — | — | US | claimed |
| EP-2057158-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | Cellzome Limited (GB) | 2009-05-13 | — | — | EP | claimed |
| WO-2008025821-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2008-03-06 | — | — | WO | claimed |
| EP-1894931-A1 | Triazole derivatives as kinase inhibitors | CELLZOME AG (DE) | 2008-03-05 | — | — | EP | claimed |
| US-20160024089-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024089-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024089-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2057158-B1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LTD (GB) | 2015-08-12 | — | — | EP | disclosed |
| US-20140378449-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140378449-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
| WO-2009155565-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| EP-2057158-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | Cellzome Limited (GB) | 2009-05-13 | — | — | EP | disclosed |
| WO-2009017954-A1 | INHIBITORS OF JAK2 KINASE | PHENOMIX CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008025821-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2008-03-06 | — | — | WO | disclosed |
| EP-1894931-A1 | Triazole derivatives as kinase inhibitors | CELLZOME AG (DE) | 2008-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378449-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | NUDT1 3080/4885EGLN2 3771/4885JAK1 2/4885 |
| US-20160024089-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | NUDT1 3080/4885EGLN2 3771/4885JAK1 2/4885 |
| US-20100227800-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | ITK, PIK3C3, TXK | NUDT1 2884/4885EGLN2 1996/4885JAK1 13/4885 |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | NUDT1 3080/4885EGLN2 3771/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.